Efferocytosis and Genomic Polymorphism in Autoimmune Diseases
NCT00364728 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 450
Last updated 2010-05-21
Summary
Over the past few years, growing evidences revealed that clearance of apoptotic cells by phagocytosis can result in powerful anti-inflammatory and immunosuppressive effects. In vivo, apoptotic cells are cleared rapidly by neighboring cells, macrophages and related scavengers. Defective clearance of apoptotic cells has been linked closely to autoimmunity and persistent inflammatory disease. Several phagocytic receptors, bridging molecules produced by phagocytes and 'eat-me' signals on apoptotic cells are coordinately involved in mediating clearance of apoptotic cells. Complement receptors (CR3, CR4), collection, CD14, CD36 (Class B scavenger receptor), class A scavenger receptor, asialoprotein receptor, Mer receptor kinase were reported to recognize apoptotic cells. The best characterized system for clearance of apoptotic cells is the recognition of phosphatidylserine (PS) on apoptotic cells by phosphatidylserine receptor (PSR). Milk fat globule- epidermal growth factor 8 (MFG-E8) is an opsonin that bridges phagocytes (by interacting with α vβ3, αvβ5 integrins via RGD motif) and apoptotic cells (by binding PS through Factor V/VIII-C domain). Activated macrophages produce and secret MFG-E8. MFG-E8 is a critical component in PSR-mediated phagocytosis of apoptotic cells. The dominant negative mutant MFG-E8, D89E, that carried a mutated RGD motif inhibited phagocytosis of apoptotic cells in vitro. Injection of D89E into wild type mice induced autoantibodies and IgG deposition on glomeruli. Macrophages from MFG-E8 deficiency (MFG-E8-/-) mice were impaired in engulfment of apoptotic cells, which can be restored by adding recombinant MFG-E8. The female MFG-E8-/- mice spontaneously produced high titer of autoantibodies and developed lupus-like glomerulonephritis at the age of week 40. Defective clearance of apoptotic cells is closely related to development of autoimmunity. In the past 4 years, a growing number of molecules were recognized as receptors for the PS exposed on the apoptotic cells. These molecules were capable of mediating phagocytic clearance, rendering anti-inflammatory cytokines in the phagocytes, and modulating T cell responses.
The specific aim of this proposal is to study genetic polymorphism in MFG-E8, PSR and other factors implicated in phagocytic clearance of apoptotic cells among Taiwanese. By comparing the polymorphism between patients with autoimmune disease (SLE or RA) and healthy control subjects, we will investigate if genetic variations among individuals of genes encoding proteins involved in clearance of apoptotic cells contribute to the pathogenesis of systemic autoimmune diseases SLE and RA.
Conditions
- SLE
- Rheumatoid Arthritis
- Healthy Subjects
Sponsors & Collaborators
-
National Taiwan University Hospital
lead OTHER
Principal Investigators
-
Chung-Yi Hu, PhD · Department of Clinical Laboratory Sciences and Medical Biotechnology
Eligibility
- Min Age
- 20 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2006-01-31
- Primary Completion
- 2012-07-31
- Completion
- 2012-07-31
Countries
- Taiwan
More Related Trials
-
An Observational Study of Patients With Autoimmune Disease
NCT05842824 ·Status: NOT_YET_RECRUITING
-
Equecabtagene Autoleucel Injection (Eque-cel) for Relapsed/Refractory Systemic Lupus Erythematosus (SLE)
NCT06902844 ·Status: RECRUITING ·Phase: NA
-
Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine
NCT00775476 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Efficacy and Safety of Low-dose IL-2 in Patients With SLE: a Multicenter, Randomised, Placebo-controlled Trial
NCT04077684 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase II Study to Evaluate the Efficacy and Safety of SHR-1314 in Lupus Nephritis
NCT04924296 ·Status: UNKNOWN ·Phase: PHASE2
-
Safety and Efficacy Study of CC312 for Moderate to Severe SLE
NCT07177911 ·Status: RECRUITING ·Phase: PHASE1
-
Establishing the Salience of Type 1 Interferon Pathway Blockade in the Central Mechanisms of SLE Related Fatigue
NCT06784076 ·Status: NOT_YET_RECRUITING
-
Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus
NCT02446899 ·Status: COMPLETED ·Phase: PHASE3
-
Study Evaluating the Pharmacokinetics and Safety of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE)
NCT01449071 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Ferroptosis Role in the Pathophysiology of Systemic Lupus Erythematosus
NCT07260942 ·Status: RECRUITING ·Phase: NA
-
Neutrophil Extracellular Traps in Systemic Sclerosis
NCT03374618 ·Status: COMPLETED ·Phase: NA
-
The Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HC022 Injection in Subjects With SLE/CLE
NCT07306585 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Safety Study of CC312 in Autoimmune Disease Patients
NCT06888960 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus
NCT02535689 ·Status: COMPLETED ·Phase: PHASE1
-
Dual Target CAR-T Cell Treatment for Refractory Systemic Lupus Erythematosus (SLE) Patients
NCT05858684 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
NCT01408576 ·Status: COMPLETED ·Phase: PHASE3
-
Universal Anti-CD70 CAR-T (CHT101) Cell Therapy for Relapsed Refractory Systemic Lupus Erythematosus
NCT06946485 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE)
NCT01261793 ·Status: COMPLETED ·Phase: PHASE3
-
Anti-infection of Low-does IL-2 in SLE
NCT02932137 ·Status: COMPLETED ·Phase: NA
-
A Study of CAR-T Cells in Subjects With Systemic Lupus Erythematosus
NCT06900764 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
NCT06434363 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Clinical Autoinflammatory Disease Cohort
NCT07126145 ·Status: NOT_YET_RECRUITING
-
The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD
NCT05440422 ·Status: RECRUITING ·Phase: PHASE2
-
A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
NCT06978647 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of CC312 for Relapsed/Refractory Autoimmune Diseases
NCT07193810 ·Status: RECRUITING ·Phase: EARLY_PHASE1